Literature DB >> 2411828

Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides.

M W Fountain, S J Weiss, A G Fountain, A Shen, R P Lenk.   

Abstract

Stable plurilamellar vesicles (SPLVs) entrapping aminoglycosides were used to treat infections due to Brucella species (Brucella canis and Brucella abortus). SPLV-entrapped antibiotics effectively eliminated internalized B. canis in cultures of resident murine peritoneal macrophages and internalized B. abortus in cultures of resident guinea pig peritoneal macrophages. In vivo studies demonstrated that SPLV-entrapped aminoglycosides administered to B. canis-infected mice and B. abortus-infected guinea pigs effectively eliminated bacteria from infected organs. The dosage schedule used involved two intraperitoneal administrations of SPLV-entrapped aminoglycosides at three-day intervals. The results demonstrate the superiority of SPLV-entrapped aminoglycosides to free aminoglycosides in effecting elimination of facultative intracellular bacteria in vitro and in vivo. The use of SPLVs as a drug carrier has broad application to treatment of infections due to other organisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411828     DOI: 10.1093/infdis/152.3.529

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice.

Authors:  M C Lecaroz; M J Blanco-Prieto; M A Campanero; H Salman; C Gamazo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 3.  Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience.

Authors:  A Coune
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

Review 4.  Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.

Authors:  I A Bakker-Woudenberg; A F Lokerse; M T ten Kate; P M Melissen; W van Vianen; E W van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

Review 5.  Liposomes and nanoparticles in the treatment of intracellular bacterial infections.

Authors:  P Couvreur; E Fattal; A Andremont
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

6.  Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.

Authors:  C Beaulac; S Clément-Major; J Hawari; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 7.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 8.  Liposomes in treatment of infectious diseases.

Authors:  F Emmen; G Storm
Journal:  Pharm Weekbl Sci       Date:  1987-06-19

9.  Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin.

Authors:  B Shasha; R Lang; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

Authors:  J Ariza; J Bosch; F Gudiol; J Liñares; P F Viladrich; R Martín
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.